Interferon (IFN) regulatory factor-1 (IRF-1) is a transcription factor that has apoptotic anti-tumor activity. In breast cancer cell types, IRF-1 is implicated in mediating apoptosis by both novel and ...

Which patients are more likely to develop a severe form of COVID-19? In a new study, researchers describe a unique and unexpected immunological phenotype in severe and critical patients. Which ...

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma PEG-IFN (1, 2, and 3 μg/kg per week) was ...

Interferon-α nasal spray was safe and effective in reducing COVID-19 risk by 40% in patients with cancer, demonstrating its potential as an additional preventive strategy alongside vaccines and ...

ATLANTA – In their continuing work to limit the impact of COVID-19, Emory University researchers have, for the first time in nonhuman primates, studied how modulating the signaling of type 1 ...

In a recent study posted to the medRxiv* preprint server, a team of researchers characterized the expression of type-1 and type-2 interferons (IFN-1 and IFN-2), interferon-stimulated genes (ISGs), and ...

Please provide your email address to receive an email when new articles are posted on . “These findings suggest that IFN-I blocking agents may be particularly effective in treating skin manifestations ...

A team of scientists from Sweden and India has recently conducted a study to evaluate type I interferon (IFN-I) responses in cells infected with severe acute respiratory syndrome coronavirus 2 ...

Four hundred eighty-eight patients were randomly assigned to five treatment groups: DTIC+IFN-α+Tα1 (1.6 mg); DTIC+IFN-α+Tα1 (3.2 mg); DTIC+IFN-α+Tα1 (6.4 mg); DTIC+Tα1 (3.2 mg); DTIC+IFN-α (control ...

Placebo B-G:RG7128 (500–1000 mg) + danoprevir (100–200 mg) × 14 days E: RG7128(1000 mg) + danoprevir (600 mg) × 14 days F: RG7128 (1000 mg) + danoprevir (900 mg) × 14 days Grp B: (17) Grp A: BI07127 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Young patients with type 1 diabetes ...